General
Preferred name
PHENYL SALICYLATE
Synonyms
NSC-33406 ()
NSC 33406 ()
NSC33406 ()
phenyl-salicylic acid ()
FEMA NO. 3960 ()
P&D ID
PD014587
CAS
118-55-8
Tags
available
drug
Approved by
FDA
Drug Status
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Phenyl salicylate has several medical uses. It can be used as an analgesic to relieve pain, as an antiseptic with antibacterial effect as well as a kind of antipyretic for the treatment of fever. It is also used for the treatment of inflammation in the lower urinary tract. It is no longer commonly applied to human medical practice but is still used in veterinary medicine [MSDS].; ; When it is combined with methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate, it is used to relieve the discomfort, pain, frequent urge to urinate, and cramps/spasms of the urinary tract caused by a urinary tract infection or a diagnostic procedure [L2471].
TOXICITY Oral LD50 in the rat is 3000 mg/kg [L2476]; ; ; Adverse effects can be divided into several categories [L2464], [L2475]:; ; Eyes: irritation [L2475]; ; Skin: skin irritation [L2475]; ; Cardiovascular: rapid pulse, flushing [L2464]; ; Central Nervous System —blurred vision, dizziness [L2464]; ; Respiratory —shortness of breath or troubled breathing [L2464], irritation of respiratory system [L2475]; ; Genitourinary —difficult micturition, acute urinary retention [L2464]; ; Gastrointestinal —dry mouth, nausea/vomiting [L2464]; ; ; Overdosage may be managed by inducing emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children) repeated as needed in 1-2 h to relieve severe antimuscarinic symptoms. Administration of small doses of diazepam to control excitement and seizures may be warranted. Artificial respiration with oxygen can be used if needed for respiratory depression. Adequate hydration is important, as well as symptomatic treatment, provided as necessary [L2464].;
METABOLISM Hydrolyzed to salicylic acid [L2474]. Salicylic acid elimination kinetics are dependent on drug concentration because of the limited capacity of two major biotransformation pathways: formation of salicyluric acid and of salicyl phenolic glucuronide.; ; Metabolism of this drug occurs mainly in the liver, like other salicylates [A32453].; ; Metabolism of salicylic acid occurs through glucuronide formation (to produce salicyluric acid), and salicyl phenolic glucuronide), conjugation with glycine (to produce salicyluric acid), and oxidation to form gentisic acid. The rate of formation of salicyl phenolic glucuronide and salicyluric acid are easily saturated at low salicylic acid concentrations and their formation can be described by Michaelis-Menten kinetics [A32453].
PRICE 29
DESCRIPTION Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate. (Enamine Bioactive Compounds)
DESCRIPTION Phenyl salicylate (NSC-33406) is a chemical substance. It is synthesized by heating salicylic acid with phenol. (TargetMol Bioactive Compound Library)
Compound Sets
14
ChEMBL Drugs
CHEMBL1339216
Drug Repurposing Hub
DrugBank
DB11071
DrugBank Approved Drugs
DB11071
DrugCentral
3462
DrugCentral Approved Drugs
3462
DrugMatrix
Enamine Bioactive Compounds
EBC-14449
Enamine BioReference Compounds
MedChem Express Bioactive Compound Library
HY-B1731
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
phenyl-salicylate
TargetMol Bioactive Compound Library
T20250
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
214.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
2.61
TPSA
46.53
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
interstitial cystitis (IC)
MOA
antiseptic
Target
Bacterial
Pathway
Anti-infection
Source data